Skip to main content
European Commission logo print header

Development and application of transposons and site-specific integration technologies as non-viral gene delivery methods for ex vivo gene-based therapies

Final Report Summary - INTHER (Development and application of transposons and site-specific integration technologies as non-viral gene delivery methods for ex vivo gene-based therapies)

Considerable effort has been devoted to the development of gene delivery strategies for the treatment of inherited and acquired disorders in humans. Ex vivo gene therapies are based on removing cells from a patient, introducing a therapeutic gene construct into the cells, and implanting the engineered cells back into the patient. Currently, both viral and non-viral methods are used for gene delivery. Viral vectors are efficient in gene transfer, but their use raises serious safety concerns. Non-viral methods are usually safer but less efficient in providing long-term therapeutic transgene expression. Transposable elements can be considered as natural, non-viral delivery vehicles capable of efficient genomic insertion. In this project, novel gene transfer technologies will be established by developing transposon vectors that mediate efficient and targeted integration of therapeutic genes into the genome.

Therapeutic gene constructs were made in transposon vectors, and delivered into cells ex vivo, using cutting edge non-viral nucleic acid delivery methods. Application of reversible implantation systems (collagen implants, skin biopumps, and encapsulated cells) were also explored. Animal disease models included copper metabolism diseases, anemia, hypercholesterolemia, bleeding disorders, chronic grnulomatous disease and neurological disorders. Genomic insertion, transgene expression and phenotypic correction were also investigated. Safety issues of transposon vector administration and genomic integration were addressed. The involvement of three small and medium-sized enterprises (SMEs) mobilised industrial know-how and technology. This project developed, tested and applied new therapeutic tools for somatic gene therapy as an alternative to currently used viral and non-viral technologies, and have the potential to offer new solutions for diseases that impose significant impairment to citizens' quality of life, as well as burdens on health care services in Europe.